Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus FOLFIRI as second-line therapy in RAS/BRAF wild-type advanced colorectal cancer after anti-EGFR treatment
KCT0010463Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab in colorectal cancer (CRC), sponsored by Janssen Pharmaceutical. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
amivantamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on KCT0010463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010463.